Carole Nuechterlein is Director & 10% Owner at Aligos Therapeutics, Inc. (ALGS). They have made 1 open-market trade across 1 company since 2023, most recently 2023-10-25.
CIK 0001665133
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $12.1M since 2023, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ALGS | 11,025,941 | $55.0M |
Shares reported on the most recent Form 4, priced at the 2023-10-27 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALGS | BUY | 2023-10-25 | 2023-10-27 | $0.76 | $12.1M | +2.0% | -2.2% | -3.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.